You are here

Bluebird Bio

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

Forbes

Flag link:

Bluebird Bio submits BLA for sickle cell disease gene therapy

Bluebird Bio submits BLA for sickle cell disease gene therapy

Biopharma Reporter

sickle cell disease

Flag link:

Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced

Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced

Endpoints

sickle cell disease

Flag link:

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

BioPharma Dive

sickle cell disease

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Bluebird hopes to raise upwards of $100M by selling shares

Bluebird hopes to raise upwards of $100M by selling shares

Endpoints

Flag link:

Moderna Gets Good News, but Another Biotech Stock Is Falling Again

Moderna Gets Good News, but Another Biotech Stock Is Falling Again

Motley Fool

Moderna Therapeutics

Flag link:

FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies

FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies

NASDAQ

clinical trials

sickle cell disease

Flag link:

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

BioPharma Dive

Multiple Myeloma

Flag link:

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

Fierce Pharma

sickle cell disease

Flag link:

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Benzinga

priority review vouchers

Flag link:

ASH preview – waiting for Editas

ASH preview – waiting for Editas

EP Vantage

sickle cell disease

Sangamo BioSciences

Editas Medicine

Vertex Pharmaceuticals

Flag link:

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Flag link:

Bluebird wins FDA approval of gene therapy for rare brain disorder

Bluebird wins FDA approval of gene therapy for rare brain disorder

BioPharma Dive

Flag link:

Go or no go? Bristol’s Tyk2 test

Go or no go? Bristol’s Tyk2 test

EP Vantage

Bristol Myers Squibb

deucravacitinib

Amylyx Pharmaceuticals

Ferring Pharmaceuticals

Revance Therapeutics

Spectrum Pharmaceuticals

Flag link:

bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy

bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy

BioSpace

beta thalassemia

Flag link:

Go or no go? J&J’s bispecific FDA first

Go or no go? J&J’s bispecific FDA first

EP Vantage

Amicus Therapeutics

Flag link:

FDA Has Ways to Go to Keep Pace with 2020/21 Approvals

FDA Has Ways to Go to Keep Pace with 2020/21 Approvals

BioSpace

Bristol Myers Squibb

Flag link:

bluebird bio Soars as FDA Adcom Recommends Second Gene Therapy

bluebird bio Soars as FDA Adcom Recommends Second Gene Therapy

BioSpace

lentiviral vectors

Flag link:

FDA panel backs Bluebird gene therapy despite safety risks

FDA panel backs Bluebird gene therapy despite safety risks

BioPharma Dive

Flag link:

Bluebird bio’s future in balance as FDA weighs gene therapy approvals

Bluebird bio’s future in balance as FDA weighs gene therapy approvals

BioPharma Dive

Flag link:

Pages